AL
AVXL icon

Airain Ltd’s Anavex Life Sciences AVXL Stock Holding History

Airain Ltd’s Portfolio AVXL Stock Details AVXL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-27,466
Closed -$135K – 651
2016
Q1 		$135K Buy
+27,466
New +$121K 0.01% 719

Other funds holding AVXL

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BIM
BlackRock Investment Management Wilmington, Delaware $86.4B AUM 16.83% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Airain Ltd's AVXL Position: Q2 2016 in Review

Airain Ltd sold out of Anavex Life Sciences (AVXL) in Q2 2016, closing a stake of 27,466 shares — an estimated $135K sold.

Airain Ltd first reported a position in AVXL in Q1 2016 and held it in 1 quarter. The position peaked at $135K in Q1 2016. 46 funds tracked by Wall St. Rank hold AVXL as of Q2 2016.

  • Airain Ltd reported no remaining Anavex Life Sciences position as of Q2 2016 after selling out during the quarter.
  • Airain Ltd sold 27,466 Anavex Life Sciences shares in Q2 2016, an estimated $135K.
  • Airain Ltd first reported a position in Anavex Life Sciences in Q1 2016 and held it in 1 quarter.
  • Airain Ltd's Anavex Life Sciences position peaked at $135K in Q1 2016.
  • 46 funds tracked by Wall St. Rank held Anavex Life Sciences as of Q2 2016.

Based on Airain Ltd's 13F filing for Q2 2016, filed 5 Aug 2016.